By Sam Boughedda AbbVie (NYSE:ABBV) is looking towards its new drugs to replace Humira now that its blockbuster immune-disease therapy is facing lower-priced competition, the Wall Street...
By Johann M Cherian and Shreyashi Sanyal (Reuters) - U.S. stock indexes were set to open lower on Wednesday as investors cautiously awaited the Federal Reserve's decision on interest rates...
Amgen Inc's (NASDAQ: AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and benefited from a 4% increase in product...
Amgen (AMGN) reported Q4 EPS of $4.09, in-line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8 billion versus the consensus estimate of $6.74...
Investing.com - Amgen (NASDAQ: AMGN) reported fourth quarter EPS of $4.09, in line with the analyst estimate of $4.09. Revenue for the quarter came in at $6.8B versus the consensus estimate...
By Sam Boughedda After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a biosimilar...
By Geoffrey Smith Investing.com -- The Federal Reserve starts a two-day policy meeting against a backdrop of weakening economic data - although the International Monetary Fund has raised its...
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
(Reuters) – Amgen Inc said on Monday that it had let go about 300 employees based in the United States, mainly in its commercial team, citing recent organizational changes to better...
WASHINGTON (Reuters) – Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending...
As we head into 2023, here's a look back at a year that saw dealmaking slow into year-end amid rising interest rates by central banks, with three of the top five deals fraught with...
By Daniel Shvartsman Investing.com -- Entering the last trading day of the year, it's no surprise to find the 2022 scoreboard filled with energy winners and tech losers.The Dow Jones...
Here are the biggest fresh dividend hikes and special dividends, as first covered on InvestingPro+, including several predicted by data from InvestingPro+ and StreetInsider this month. Get a...
By Liz Moyer Investing.com -- Stocks are rising as investors await key inflation data and the Federal Reserve's decision on the next direction for interest rates. Here are the midday movers...
By Liz Moyer Investing.com -- Blue-chip stocks were rising but tech stocks wobbled as investors await inflation data and the Federal Reserve's next decision on interest rates later this...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, December 12th. Please refresh for updates. Amgen (NASDAQ:AMGN) stock fell 3.2% after the Wall Street Journal...
By Scott Kanowsky Investing.com -- Amgen Inc. (NASDAQ:AMGN) has agreed to buy Horizon Therapeutics PLC (NASDAQ:HZNP) in an all-cash deal that values the biotech firm at about $28.3 billion,...
Here are the 5 biggest deal dispatches from this past week, as covered first on InvestingPro+. Coupa Software (NASDAQ:COUP) was recently surging 26% in premarket trade Monday on news it had...
By Peter Nurse Investing.com -- U.S. stocks are seen opening marginally higher Monday, starting an important week that includes consumer inflation data and the final Federal Reserve...
By Senad Karaahmetovic Amgen (NASDAQ:AMGN) has agreed to acquire Horizon Therapeutics (NASDAQ:HZNP), according to Bloomberg News. Amgen agreed to pay $116.5 for each HZNP share, valuing the...
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) rose on Monday after the French drugmaker backed out of its plans to bid for biotech company Horizon Therapeutics PLC...
By Peter Nurse Investing.com - European stock markets retreated Monday, with investors cautious ahead of policy-setting meetings from the likes of the Federal Reserve and the European...
By Investing.com Staff Stocks were heavy Monday as positive economic data stirred concerns the Fed will have to maintain its hawkishness on rates. Amid the downside, several rumors swirled...
By Investing.com Staff Horizon Therapeutics (NASDAQ:HZNP) fell nearly 5% in early trading Monday after it was disclosed that one of the three original bidders for the company dropped...
Here are 7 head-turning deal dispatches from the past week, as covered first on InvestingPro+. 1. Arco Platform (NASDAQ:ARCE) announced it had received a non-binding going private...
By Liz Moyer Investing.com -- Stocks were struggling for direction on Wednesday as investors waited to hear what Federal Reserve Chair Jerome Powell will say in a speech he is scheduled to...
By Investing.com Staff Stocks edged lower Tuesday as traders watch developments in China around protests over the county's 'zero COVID' policy. Amid the downside action, several rumors...
By Investing.com Staff Shares of Horizon Therapeutics (NASDAQ:HZNP) surged over 30% after-hours Tuesday after the company confirmed that it was "highly preliminary" takeover talks with Amgen...
By Sam Boughedda Credit Suisse analysts said Friday that the firm is initiating coverage of U.S. large-cap pharmaceuticals with four Outperform ratings, two Neutral ratings, and one...
By Amruta Khandekar and Devik Jain (Reuters) - U.S. stock indexes rose for the third straight session on Tuesday as voting began in the crucial midterm election that will determine control...
By Liz Moyer Investing.com -- Amgen (AMGN) reported third quarter earnings that beat analysts' forecasts and revenue that topped expectations. The biotech company reported earnings per...
By Liz Moyer Investing.com -- Amgen (NASDAQ:AMGN) reported third quarter {{erl-6466||earnings that beat analysts' forecasts and revenue that topped expectations. The biotech company...
Investing.com - Amgen (NASDAQ:AMGN) reported on Thursday third quarter {{erl-6466||earnings that beat analysts' forecasts and revenue that topped expectations. Amgen announced earnings per...
Amgen (AMGN) reported Q3 EPS of $4.70, $0.25 better than the analyst estimate of $4.45. Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.58...
By Geoffrey Smith Investing.com -- The Federal Reserve's hawkish messaging drives the dollar higher and brings the rally in U.S. and global stocks to a shuddering halt. The Bank of England...
By Senad Karaahmetovic Barclays analysts downgraded shares of Amgen (NASDAQ:AMGN) to Underweight from Equal Weight with a price target of $234 per share. With Amgen shares up over 20% in...
By Davit Kirakosyan Amgen (NASDAQ:AMGN) shares were up 6% intra-day today after Morgan Stanley upgraded the company to Overweight from Equalweight and raised its price target to $279 from...
By Senad Karaahmetovic Morgan Stanley analysts upgraded shares of Amgen (NASDAQ:AMGN) to Overweight with a price target of $279 per share (up from $257). The analysts believe that the market...
By Sam Boughedda Amgen (NASDAQ:AMGN) was reiterated at Neutral with a $208 per share price target by a Mizuho analyst on Monday, despite the stock's decline during the session following the...
By Senad Karaahmetovic Shares of Bristol-Myers Squibb (NYSE:BMY) are up about 7% in premarket Monday after the U.S. FDA approved Deucravacitinib, now known as Sotyktu, for the treatment of...
Pre-Open Stock Movers: Bed Bath & Beyond Inc . (NASDAQ:BBBY) 24% LOWER; provides a strategic update, announcing job cuts, store closures, a 12 million share ATM offering, loan deal, and...
After-Hours Stock Movers:Chewy (NYSE:CHWY) 8% LOWER; reported Q2 net income of $22.3 million. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.45...
By Investing.com Staff Amgen (NASDAQ:AMGN) reported its {{erl-6466||Q2 results, with EPS of $4.65 coming in better than the consensus estimate of $4.39. Revenue grew 1% year-over-year to...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
